Lpath has won a US patent covering methods of using monoclonal antibodies for the treatment and prevention of ocular conditions, including wet age-related macular degeneration (AMD).
The patent includes the use of monoclonal antibodies, including the company's therapeutic antibody iSONEP that binds sphingosine-1-phosphate (S1P).
Lpath vice president, founder, and an inventor of the granted patent Roger Sabbadini said, "This patent provides exclusivity for iSONEP and other antibodies to 0S1P in the U.S. for ocular disorders and complements our recent exclusivity for anti-S1P antibodies in Europe for wet AMD, cancer, and other conditions."
Designed to assess the anti-S1P antibody's safety and efficacy in wet-AMD patients, the company is conducting a Phase 2 trial for iSONEP, called Nexus.
In 2010, Pfizer gained an exclusive option for a worldwide license to develop and commercialize iSONEP from Lpath.
The company leveraged ImmuneY2 drug-discovery engine in the development of different formulations of sonepcizumab, iSONEP and ASONEP.
